Staphylococci have emerged as the most significant bacterial pathogen in the community and health care institutions, causing over two million high-risk infections per year in the United States alone. Community- acquired Methicillin-Resistant Staphylococcus aureus (CA-MRSA) is responsible for Acute Lung Injury (ALI) associated with necrotizing pneumonia often complicated by Acute Respiratory Distress Syndrome (ARDS), Toxic Shock, and Disseminated Intravascular Coagulation (DIC). Health care-associated MRSA (HA-MRSA) threatens newborns in nurseries and older patients hospitalized with medical and surgical problems. Toxic shock syndrome carries significant patient mortality in children (5%) and adults (up to 80%). This syndrome is due to production of T cell-activating exotoxins ("superantigens") by antibiotic-resistant staphylococci. Their uncontrolled proliferation and production of superantigens in the lungs often occurs in the wake of influenza virus infection doubling its annual mortality (65,000 deaths). Superantigens robustly stimulate T cells to proliferate and produce overwhelming quantities of proinflammatory cytokines/chemokines that trigger lung vascular injury, apoptosis, and hemorrhagic necrosis. Our ultimate goal is to develop new therapeutic approaches to superantigen-induced ALI. During the past funding period we developed an innovative in vivo platform termed intracellular protein/peptide therapy (IPT), to suppress the uncontrolled production of proinflammatory cytokines and chemokines in animals challenged with the superantigen staphylococcal enterotoxin B (SEB). We engineered a cell-penetrating (CP-) form of the physiologic protein Suppressor of Cytokine Signaling 3 (SOCS3) that attenuated SEB-induced acute inflammation, apoptosis, and hemorrhagic necrosis of the liver. However, endogenous SOCS3 seemed insufficient to avert "spontaneous" and fatal lung inflammation in mice born with SOCS1 deficiency, rendering SOCS1 a more attractive candidate for IPT of ALI. Based on these clinically- relevant advances, the central hypothesis of this competing renewal application is that CP-SOCS1 can attenuate ALI and protect lungs from the noxious action of proinflammatory cytokines and chemokines induced by direct airway exposure to superantigens. This central hypothesis will be tested in the following specific aims: (i) To engineer CP forms of SOCS1 that target noxious signaling evoked by T cell- derived inflammatory cytokines/chemokines in response to SEB exposure;(ii) To compare lung cytoprotective activity of CP-SOCS1 and CP-SOCS3 as a countermeasure for ALI/ARDS including antecedent influenza virus infection and (iii) To determine the inhibitory mechanism of CP-SOCS1 action in SEB-induced disease. Results from these studies will meet the urgent need for new anti-inflammatory drugs that attenuate acute lung vascular injury and DIC evoked by staphylococcal superantigens that often work in tandem with other viral and bacterial pathogens.

Agency
National Institute of Health (NIH)
Institute
National Heart, Lung, and Blood Institute (NHLBI)
Type
Research Project (R01)
Project #
5R01HL069452-08
Application #
7990437
Study Section
Hemostasis and Thrombosis Study Section (HT)
Program Officer
Sarkar, Rita
Project Start
2001-09-30
Project End
2013-11-30
Budget Start
2010-12-01
Budget End
2013-11-30
Support Year
8
Fiscal Year
2011
Total Cost
$383,750
Indirect Cost
Name
Vanderbilt University Medical Center
Department
Internal Medicine/Medicine
Type
Schools of Medicine
DUNS #
004413456
City
Nashville
State
TN
Country
United States
Zip Code
37212
Wylezinski, Lukasz S; Hawiger, Jacek (2016) Interleukin 2 Activates Brain Microvascular Endothelial Cells Resulting in Destabilization of Adherens Junctions. J Biol Chem 291:22913-22923
Hawiger, J; Veach, R A; Zienkiewicz, J (2015) New paradigms in sepsis: from prevention to protection of failing microcirculation. J Thromb Haemost 13:1743-56
DiGiandomenico, Antonio; Veach, Ruth Ann; Zienkiewicz, Jozef et al. (2014) The "genomic storm" induced by bacterial endotoxin is calmed by a nuclear transport modifier that attenuates localized and systemic inflammation. PLoS One 9:e110183
Qiao, Huan; Liu, Yan; Veach, Ruth A et al. (2014) The adaptor CRADD/RAIDD controls activation of endothelial cells by proinflammatory stimuli. J Biol Chem 289:21973-83
Lin, Qing; Liu, Yan; Moore, Daniel J et al. (2012) Cutting edge: the "death" adaptor CRADD/RAIDD targets BCL10 and suppresses agonist-induced cytokine expression in T lymphocytes. J Immunol 188:2493-7
Fletcher, Tynetta C; DiGiandomenico, Antonio; Hawiger, Jacek (2010) Extended anti-inflammatory action of a degradation-resistant mutant of cell-penetrating suppressor of cytokine signaling 3. J Biol Chem 285:18727-36
DiGiandomenico, Antonio; Wylezinski, Lukasz S; Hawiger, Jacek (2009) Intracellular delivery of a cell-penetrating SOCS1 that targets IFN-gamma signaling. Sci Signal 2:ra37
Liu, Danya; Zienkiewicz, Jozef; DiGiandomenico, Antonio et al. (2009) Suppression of acute lung inflammation by intracellular peptide delivery of a nuclear import inhibitor. Mol Ther 17:796-802
Zanchi, Cristina; Zoja, Carla; Morigi, Marina et al. (2008) Fractalkine and CX3CR1 mediate leukocyte capture by endothelium in response to Shiga toxin. J Immunol 181:1460-9
Carter, Robert S; Pennington, Kevin N; Arrate, Pia et al. (2005) Site-specific monoubiquitination of IkappaB kinase IKKbeta regulates its phosphorylation and persistent activation. J Biol Chem 280:43272-9